Coherus Oncology CHRS
NASDAQ CHRS
$0.99 -0.08 (-7.48%)
At close: Oct 16, 2026 · 4:00 PM EDT

Coherus Oncology (CHRS) Depreciation & Amortization (CF) (2013 - 2026)

Updated

Coherus Oncology's Depreciation & Amortization (CF) was $862,000 in Q2 2026, down 15.2% from $1.02 million a year earlier and down 2.2% from the prior quarter.

Analysis

Coherus Oncology (CHRS) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends

On a trailing twelve-month basis, Coherus Oncology's Depreciation & Amortization (CF) was $3.61 million through Jun 30, 2026, down 22.4% year-over-year; for FY2025, it was $3.92 million, down 25.6% from FY2024.

  • Depreciation & Amortization (CF) shows a five-year compound annual growth rate of 6.3% (FY2020 to FY2025).
  • In earlier years, Depreciation & Amortization (CF) was $5.28 million in FY2024 (+39.2%), $3.79 million in FY2023 (+2.5%), $3.7 million in FY2022 (+7.1%) and $3.45 million in FY2021 (+19.6%).
  • The Q2 2026 figure marks the lowest quarterly Depreciation & Amortization (CF) since Q1 2022.
  • Compared with a year earlier, Depreciation & Amortization (CF) has declined for seven straight quarters, with an average decline of 7.2% over the last eight quarters.
  • The best year-over-year quarter for Depreciation & Amortization (CF) over five years was Q3 2024 (growth of 72.3%); the worst was Q3 2025 (a decline of 37.6%).
  • Per Business Quant data, CHRS's Depreciation & Amortization (CF) in the three quarters before Q2 2026 was $881,000 (Q1 2026), $896,000 (Q4 2025) and $966,000 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Dep. & Amort. (Qtr)
1 Eli Lilly 1,122.91 Bn 1,091.50 Bn 19.71 Bn 534.00 Mn
2 Johnson & Johnson 615.09 Bn 533.62 Bn 17.26 Bn 1.96 Bn
3 AbbVie 504.75 Bn 477.86 Bn 12.70 Bn 194.00 Mn
4 Merck 360.18 Bn 314.55 Bn 12.21 Bn 599.00 Mn
5 Novartis Ag 292.05 Bn 256.04 Bn 11.24 Bn -
6 Astrazeneca 256.09 Bn 229.78 Bn 12.86 Bn 1.93 Bn
7 Amgen 233.63 Bn 189.02 Bn 7.24 Bn 1.11 Bn
8 Gilead Sciences 194.49 Bn 168.69 Bn 6.22 Bn 98.00 Mn
9 Pfizer 168.35 Bn 114.99 Bn 10.94 Bn 1.62 Bn
10 Coherus Oncology 155.59 Mn -480.55 Mn 10.07 Mn 862,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 862,000.00
Mar 31, 2026 881,000.00
Dec 31, 2025 896,000.00
Sep 30, 2025 966,000.00
Jun 30, 2025 1.02 Mn
Mar 31, 2025 1.05 Mn
Dec 31, 2024 1.03 Mn
Sep 30, 2024 1.55 Mn
Jun 30, 2024 1.19 Mn
Mar 31, 2024 1.51 Mn
Dec 31, 2023 1.06 Mn
Sep 30, 2023 899,000.00
Jun 30, 2023 880,000.00
Mar 31, 2023 949,000.00
Dec 31, 2022 1.05 Mn
Sep 30, 2022 900,000.00
Jun 30, 2022 900,000.00
Mar 31, 2022 767,000.00
Dec 31, 2021 836,000.00
Sep 30, 2021 900,000.00
API Access

Coherus Oncology Depreciation & Amortization (CF) API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=depreciation-and-amortization-cf&ticker=CHRS&period=max&api_key=YOUR_API_KEY